Personalized Comorbidity-Integrated Gout Care

个性化合并症综合痛风护理

• 批准号: 10663477
• 负责人: Chio Yokose
• 金额: $ 17.6万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-07-01 至 2028-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10663477
• 关键词: Address; Adherence; Affect; Agonist; Angiotensin-Converting Enzyme Inhibitors; Area; Biological Markers; Biology; Calcium Channel Blockers; Caring; Chronic Kidney Failure; Clinic; Clinical; Clinical effectiveness; Comparative Effectiveness Research; Data; Development; Diabetes Mellitus; Diagnosis; Doctor of Philosophy; East Asian; Electronic Health Record; Emergency department visit; Enrollment; Environment; Epidemiology; Evolution; Exhibits; Faculty; Fellowship; Flare; Funding; GLP-I receptor; General Hospitals; Glucose; Goals; Gout; Guidelines; Heart Diseases; Hospitalization; Hypersensitivity; Immunology; Inflammatory Arthritis; Internal Medicine; K-Series Research Career Programs; Losartan; Manuscripts; Massachusetts; Medical Informatics; Medicine; Mendelian randomization; Mentors; Mentorship; Methodology; Methods; Modeling; Morbidity - disease rate; New York; Outcome; Outcome Measure; Outcomes Research; Patient Outcomes Assessments; Patient-Focused Outcomes; Patients; Pattern; Peer Review; Pharmaceutical Preparations; Pharmacoepidemiology; Phenotype; Physicians; Premature Mortality; Prevalence; Probability; Public Health Schools; Randomized, Controlled Trials; Recommendation; Registries; Research; Research Personnel; Residencies; Rheumatology; Risk; Risk Factors; Serum; Sodium; Time; Training; Training Activity; United States National Institutes of Health; Universities; Urate; active comparator; burden of illness; cardiometabolic risk; cardiometabolism; cohort; comorbidity; comparative effectiveness; comparative effectiveness study; data centers; data registry; effectiveness research; evidence base; experience; hypertension treatment; illness perceptions; improved; improved outcome; inhibitor; instructor; medical schools; mortality; patient oriented; patient safety; personalized care; prevent; prospective; response; skill acquisition; symporter; treatment guidelines; trend

Candidate: Chio Yokose, MD, MSc is an Instructor in Medicine at Harvard Medical School (HMS) and an Assistant in Medicine in the Division of Rheumatology, Allergy, and Immunology at Massachusetts General Hospital (MGH). After graduating Brown University magna cum laude with her BA in Biology and East Asian Studies, she received her MD from Northwestern University. She completed her internal medicine residency at New York University and her rheumatology fellowship at MGH. She also received her MSc in Epidemiology from the Harvard T.H. Chan School of Public Health. Dr. Yokose conducts patient-centered research focused on gout and its cardiometabolic comorbidities under the mentorship of Hyon Choi, MD, DrPH. Her research has resulted in 17 peer-reviewed original manuscripts (eight as first-author). Her goal is to become an independent investigator and leader in personalized, patient-centered gout research. Mentorship, Training Activities, and Environment: Dr. Yokose will conduct the proposed project at MGH under the mentorship of Hyon Choi, MD, DrPH and co-mentorship of David W. Bates, MD, MSc and Maria Edelen, PhD. Dr. Choi is a world-renowned, NIH-funded physician investigator with expertise in advanced epidemiologic methodologies and risk factors for incident gout. Dr. Bates is a preeminent expert on leveraging medical informatics to conduct patient safety, quality, and clinical effectiveness research. Dr. Edelen has extensive expertise in the development, implementation, analysis, and interpretation of patient-reported outcomes measures (PROMs). Drs. Choi, Bates, and Edelen all have extensive experience mentoring trainees and junior faculty, including multiple prior K awardees. Dr. Yokose will also benefit from the specific expertise of her key collaborators, including pharmacoepidemiology methods and latent class analysis. Under the guidance of her mentorship team, she will acquire skills in new research areas including comparative effectiveness research, research using real-world data, and patient-centered outcomes research using biomarkers and PROMs. Research: The morbidity and mortality burden of gout and its cardiometabolic comorbidities continues to rise. These trends highlight the limitations of our current gout care model in which gout and comorbidities are managed independently. The central goal of this research is to examine the gout benefits of pleiotropic cardiometabolic medications and identify a framework for the personalized integration of gout and comorbidity care to synergistically address gout and comorbidities and ultimately improve outcomes for patients with gout. To achieve this, Dr. Yokose will conduct rigorous comparative effectiveness research examining the serum urate- lowering potential of common cardiometabolic medications (Aim 1) and determine comorbidity phenotypes of incident gout and their relations with serum urate change (key causal precursor to gout) and PROMs related to gout care barriers (Aim 2). By completing this proposal and training plan, Dr. Yokose will gain critical experience to become an independent clinical researcher and leader in personalized, patient-oriented gout research.

候选人：医学博士Chio Yokose，MSC是哈佛医学院（HMS）的医学教练 马萨诸塞州风湿病学，过敏和免疫学的医学助理 医院（MGH）。毕业后，布朗大学麦格纳（Magna Cum Laude）以她的生物学学士学位和东亚文学学士学位 研究，她从西北大学获得了医学博士学位。她在 纽约大学和她在MGH的风湿病学奖学金。她还从 哈佛T.H.陈公共卫生学院。 Yokose博士进行的以患者为中心的研究专注于痛风 及其在医学博士Hyon Choi，DRPH的指导下的心脏代谢合并症。她的研究导致了 在17个同行评审的原始手稿中（八个作为第一任作者）。她的目标是成为独立 个性化，以患者为中心的痛风研究的研究者和领导者。 指导，培训活动和环境：Yokose博士将在MGH进行拟议项目 在医学博士Hyon Choi的指导下 博士学位。 Choi博士是一位世界知名的NIH资助的医师调查员，具有高级流行病学专业知识 事件痛风的方法和风险因素。贝茨博士是利用医疗的杰出专家 提供有关患者安全，质量和临床有效性研究的信息学。 Edelen博士有广泛的 在患者报告的结果的开发，实施，分析和解释方面的专业知识 措施（舞会）。博士。崔，贝茨和埃德伦都有丰富的经验指导学员和初中 教师，包括多个先前的K获奖者。 Yokose博士还将受益于她的钥匙的具体专业知识 合作者，包括药物ePIDEMIology方法和潜在类别分析。在她的指导下 指导团队，她将在新的研究领域获得技能，包括比较有效性研究， 使用现实世界中的数据以及以患者为中心的结果研究使用生物标志物和舞会进行研究。 研究：痛风及其心脏代谢合并症的发病率和死亡率负担不断上升。 这些趋势突出了我们当前的痛风护理模型的局限性，在这种模型中，痛风和合并症是 独立管理。这项研究的核心目标是检查多效性的痛风益处 心脏代谢药物并确定痛风和合并症个性化整合的框架 注意协同解决痛风和合并症，并最终改善痛风患者的预后。 为了实现这一目标，Yokose博士将进行严格的比较有效性研究，以研究血清尿素 - 降低常见心脏代谢药物的潜力（AIM 1）并确定合并症表型 事件痛风及其与血清尿酸尿酸尿酸盐变化的关系（痛风的关键因果前体）和与 痛风护理障碍（AIM 2）。通过完成此建议和培训计划，Yokose博士将获得重要的经验 成为一个独立的临床研究人员和个性化，面向患者的痛风研究的领导者。

项目成果

Serum urate change among gout patients treated with sodium-glucose cotransporter type 2 inhibitors vs. sulfonylurea: A comparative effectiveness analysis.

使用钠-葡萄糖协同转运蛋白 2 型抑制剂与磺酰脲类药物治疗的痛风患者的血清尿酸变化：比较有效性分析。

• DOI: 10.1016/j.semarthrit.2024.152441
• 发表时间: 2024
• 期刊: Seminars in arthritis and rheumatism
• 影响因子: 5
• 作者: Yokose,Chio;Challener,Greg;Jiang,Bohang;Zhou,Baijun;McCormick,Natalie;Tanikella,Sruthi;Panchot,KilaMeiQin;Kohler,MinnaJ;Yinh,Janeth;Zhang,Yuqing;Bates,DavidW;Januzzi,JamesL;Sise,Meghan;Wexler,Deborah;Choi,HyonK
• 通讯作者: Choi,HyonK